How should the dose of apixaban be adjusted in adults based on age, weight, renal function, hepatic function, and concomitant P‑glycoprotein inhibitors?

Apixaban Dose Adjustment

For atrial fibrillation, start with apixaban 5 mg twice daily, and reduce to 2.5 mg twice daily ONLY if the patient meets at least TWO of three specific criteria: age ≥80 years, body weight ≤60 kg, OR serum creatinine ≥1.5 mg/dL. 1

Standard Dosing Framework

Atrial Fibrillation (Stroke Prevention)

• Standard dose: 5 mg twice daily
• Reduced dose: 2.5 mg twice daily

Dose reduction criteria (must meet ≥2 of the following):

• Age ≥80 years
• Body weight ≤60 kg
• Serum creatinine ≥1.5 mg/dL

2, 3, 1

Other Indications

• DVT/PE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily 1
• DVT/PE recurrence prevention: 2.5 mg twice daily (after ≥6 months initial treatment) 1
• Post-hip/knee replacement: 2.5 mg twice daily 1

Renal Function Considerations

Critical point: Unlike other DOACs, apixaban does NOT require dose adjustment based solely on renal function for atrial fibrillation. Only 27% of apixaban is renally excreted. 2

However, serum creatinine ≥1.5 mg/dL counts as ONE criterion toward the two-criterion threshold for dose reduction. Recent real-world data shows dose-adjusted apixaban concentrations are 3.3-fold higher in patients with GFR <30 mL/min compared to GFR >90 mL/min 4, suggesting patients with severe renal impairment may require around 70% lower doses.

For dialysis patients: Apixaban exposure increases by 36% post-dialysis and 17% pre-dialysis, but dialysis clearance is minimal (18 mL/min). 1 No specific dose adjustment is mandated by FDA labeling, but clinical judgment is warranted.

Drug Interactions Requiring Dose Adjustment

Reduce from 5 mg to 2.5 mg twice daily when apixaban is combined with dual P-glycoprotein AND strong CYP3A4 inhibitors, including:

• Ketoconazole (systemic)
• Itraconazole
• Ritonavir
• Clarithromycin

2, 1

If patient is already on 2.5 mg twice daily, AVOID apixaban entirely when these dual inhibitors are used. 2

Common Clinical Pitfall: Single Pathway Inhibitors

Amiodarone and diltiazem are frequently encountered but are NOT strong dual inhibitors per FDA labeling—they primarily inhibit P-glycoprotein. However, real-world data shows:

• Amiodarone alone increases apixaban trough concentrations by ~50% 5
• Diltiazem with rosuvastatin increases peak concentrations by ~50% 5
• Both drugs significantly increase bleeding risk in large Medicare cohorts 6

Clinical approach: While FDA labeling does not mandate dose reduction for amiodarone or diltiazem alone, consider measuring anti-Xa levels in high-risk patients (elderly, low body weight, renal impairment) receiving these combinations, as concentrations may exceed therapeutic ranges. 5, 7

Avoid apixaban with rifampin and other strong P-glycoprotein/CYP3A4 inducers (carbamazepine, phenytoin, St. John's wort). 2, 1

Hepatic Function

No dose adjustment needed for hepatic impairment per FDA labeling and guidelines. 2, 1

Body Weight Considerations

Body weight ≤60 kg is ONE criterion for dose reduction (must still meet one additional criterion). Recent data shows patients with extremely low body weight (≤50 kg) have significantly higher peak concentrations, with 25.6% exceeding expected ranges versus 3.7% in normal weight patients. 8 Low body weight was the only independent predictor of exceeding therapeutic peak levels (adjusted OR 4.87).

For patients <50 kg: Strongly consider the 2.5 mg twice daily dose even if they meet only one other criterion, given the substantially elevated drug levels observed.

Age-Related Adjustments

Age ≥80 years is ONE criterion for dose reduction. Age 75-79 years does NOT trigger dose reduction for apixaban (unlike dabigatran). 2, 3

Population pharmacokinetic studies show age alone results in <25% change in exposure compared to reference patients. 9

Critical Warnings About Inappropriate Dosing

Underdosing is common and harmful: In a large U.S. cohort, 61% of patients receiving reduced-dose apixaban did NOT meet criteria for dose reduction. 10 Inappropriate low-dose apixaban was associated with 77% higher mortality (adjusted HR 1.77,95% CI 1.66-1.88) compared to appropriate full-dose therapy, though stroke rates were similar. 10

Key principle: Do not empirically reduce the dose based on "clinical judgment" or perceived bleeding risk without meeting the specific two-criterion threshold. Underdosing increases mortality without clear stroke prevention benefit.

Practical Algorithm

1. Start with 5 mg twice daily as default
2. Count criteria met:
   • Age ≥80? (Yes = 1 point)
   • Weight ≤60 kg? (Yes = 1 point)
   • Serum creatinine ≥1.5 mg/dL? (Yes = 1 point)
3. If ≥2 criteria met: Use 2.5 mg twice daily
4. Check for dual P-gp/CYP3A4 inhibitors:
   • If present AND patient on 5 mg: Reduce to 2.5 mg
   • If present AND patient already on 2.5 mg: Avoid apixaban
5. Special consideration: If weight <50 kg, strongly favor 2.5 mg dose even with only one other criterion